title: Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL).
abstract: Many adult T-cell leukaemia/lymphoma (ATLL) patients who respond to induction treatment, then relapse. Knowing the clonality pattern of residual tumourous clones during treatment could help understand disease evolution and aid therapeutic decisions. We developed a sensitive and semi-quantitative molecular analysis of these clones in ATLL patients. DNA samples from PBMCs derived from eight ATLL patients were studied over time by quadruplicate linker mediated PCR (LMPCR) amplification of HTLV-1 integration sites. Patients were treated with combination chemotherapy, zidovudine-interferon-alpha and/or by peripheral stem cell transplantation or allogeneic bone marrow transplantation. Persistence of tumourous clones at a high frequency (>1/300 PBMCs) was frequently observed, even in complete responders, and was invariably correlated with relapse and/or poor outcome. Fluctuation in the frequency of some tumourous clones was observed with evidence for clonal change under treatment in one patient, indicating that treatment of ATLL can result in the selection of resistant clones. Finally, allogeneic bone marrow transplantation (BMT) using an HTLV-1 infected sibling as donor was found to be associated with long-lasting disappearance of tumourous clones and a possible cure of the disease. Long-term persistent clonal expansion of circulating HTLV-1 bearing T cells which derived from the donor bone marrow was evidenced in this patient. In conclusion, variable success in treatment of ATLL is probably due to the clonal heterogeneity which results in the selection of resistant clones. Semi-quantitative assessment of residual disease (RD) through LMPCR may predict treatment failure. Accordingly, additional therapy may be tailored to the clonality pattern observed after first-line therapy.
authors.affiliation: Unité 124 INSERM, Institut de Recherche sur le Cancer de Lille.
authors.forename: I
authors.initials: I
authors.lastname: Leclercq
authors.forename: F
authors.initials: F
authors.lastname: Mortreux
authors.forename: F
authors.initials: F
authors.lastname: Morschhauser
authors.forename: P
authors.initials: P
authors.lastname: Duthilleul
authors.forename: C
authors.initials: C
authors.lastname: Desgranges
authors.forename: A
authors.initials: A
authors.lastname: Gessain
authors.forename: M
authors.initials: M
authors.lastname: Cavrois
authors.forename: J P
authors.initials: JP
authors.lastname: Vernant
authors.forename: O
authors.initials: O
authors.lastname: Hermine
authors.forename: E
authors.initials: E
authors.lastname: Wattel
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D002999:Clone Cells; D005260:Female; D006679:HIV Seropositivity; D015368:Human T-lymphotropic virus 1; D006801:Humans; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction / Q000379:methods; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology* / Q000628:therapy